Results 91 to 100 of about 56,538 (251)

Fingolimod in the treatment of relapsing–remitting multiple sclerosis: long-term experience and an update on the clinical evidence

Therapeutic Advances in Neurological Disorders, 2016
Since the approval in 2010 of fingolimod 0.5 mg (Gilenya; Novartis Pharma AG, Basel, Switzerland) in the USA as an oral therapy for relapsing forms of multiple sclerosis, long-term clinical experience with this therapy has been increasing.
Bhupendra O. Khatri
doaj   +1 more source

Plasma Proteomics Identifies Thousand‐and‐One–Amino Acid Kinase 3 as a Potential Biomarker of Rheumatoid Arthritis Activity and a Novel Therapeutic Target

Arthritis &Rheumatology, EarlyView.
Objective Bone destruction associated with active rheumatoid arthritis (RA) remains a major therapeutic challenge, with a lack of reliable molecular markers reflecting bone injury. This study aims to identify novel biomarkers linked to bone destruction in active RA through proteomic analysis, providing new strategies for precise monitoring and targeted
Pengfei Xin, Wenzhen Li, Xinyu A, Jun Shen, Xiaohui Meng, Yanqin Bian, Haihui Han, Zheng Xiang, Lei Ran, Songtao Sun, Jun Xie, Tao Yue, Qi Zhu, Xiaoming Zhang, Lu Xie, Lianbo Xiao   +15 more
wiley   +1 more source

Non-traumatic Acute Epidural Hematoma in Multiple Sclerosis Treated With Fingolimod

Frontiers in Neurology, 2019
Fingolimod acts as a functional antagonist of the sphingosine-1-phosphate receptor and is widely used for relapsing-remitting multiple sclerosis (MS).
Ryoko Fukai, Keita Takahashi, Hiroyuki Abe, Yuichi Higashiyama, Hiroshi Doi, Hideyuki Takeuchi, Fumiaki Tanaka   +6 more
doaj   +1 more source

Immune complexes shape the pathogenicity of autoantibodies in systemic autoimmune diseases: Insights from an FcγRIIIA‐reporter assay

Arthritis &Rheumatology, Accepted Article.
Objective Immune complexes (IC), formed by autoantigen and autoantibody, play a pathogenic role in systemic autoimmune diseases through stimulation of Fcγ receptors (FcγR). However, studies investigating bioactivity of circulating IC across various diseases remain limited.
Koji Suzuki, Masaru Takeshita, Yuki Imai, Hiroyuki Fukui, Kazunori Furuhashi, Kotaro Matsumoto, Jun Kikuchi, Keiko Yoshimoto, Yuko Kaneko   +8 more
wiley   +1 more source

Metabolic pathways as possible therapeutic targets for progressive multiple sclerosis

Neural Regeneration Research, 2017
Unlike relapsing remitting multiple sclerosis, there are very few therapeutic options for patients with progressive forms of multiple sclerosis. While immune mechanisms are key participants in the pathogenesis of relapsing remitting multiple sclerosis ...
Rebecca M Heidker, Mitchell R Emerson, Steven M LeVine   +2 more
doaj   +1 more source

Silent progression in disease activity-free relapsing multiple sclerosis. [PDF]

, 2019
ObjectiveRates of worsening and evolution to secondary progressive multiple sclerosis (MS) may be substantially lower in actively treated patients compared to natural history studies from the pretreatment era.
Baranzini, Sergio E, Barba, Patrick, Bevan, Carolyn, Bischof, Antje, Bove, Riley, Caverzasi, Eduardo, Cree, Bruce AC, Gelfand, Jeffrey M, Gomez, Refujia, Goodin, Douglas S, Graves, Jennifer, Green, Ari J, Gundel, Tristan, Hauser, Stephen L, Henry, Roland G, Hollenbach, Jill A, Kirkish, Gina, Oksenberg, Jorge R, Papinutto, Nico, Ragan, Nicholas R, Romeo, Andrew, Rush, Gillian Q, Sacco, Simone, Santaniello, Adam, Stern, William A, University of California, San Francisco MS-EPIC Team, Wilson, Michael R, Zamvil, Scott S, Zhao, Chao, Zhu, Alyssa H   +29 more
core   +1 more source

Early‐stage health technology assessment of a curative gene therapy for multiple sclerosis

British Journal of Clinical Pharmacology, EarlyView.
Aims Multiple sclerosis (MS) is associated with significant early morbidity, reduced life expectancy and substantial healthcare and societal costs. The primary objective of this study is to assess the early cost‐effectiveness potential of a novel gene therapy, IMMUTOL, for MS compared with current high‐efficacy treatment sequences.
Attila Imre, Balázs Nagy, Rok Hren
wiley   +1 more source

Epidemiology of Multiple Sclerosis in Fars Province

مجله اپیدمیولوژی ایران, 2014
Background & Objectives : Multiple Sclerosis is a chronic progressive disease with several disabilities for patients. Its distribution in the world can be an important clue to study racial, genetic, and environmental factors; thus, epidemiologic studies ...
S Izadi, AR Nikseresht, M Poursadeghfard
doaj  

Evaluation of Serum Auto Antibodies in Multiple Sclerosis Patients: A Case Control Study

International Clinical Neuroscience Journal, 2017
Background and Purpose: Multiple sclerosis (MS) is believed to be an immune-mediated disorder that develops from an interaction of the individual’s genetic and as yet unidentified environmental causes.
Sadegh Izadi, Saeede Khoshniat
doaj   +1 more source

Effectiveness of delayed-release dimethyl fumarate on patient-reported outcomes and clinical measures in patients with relapsing-remitting multiple sclerosis in a real-world clinical setting: PROTEC. [PDF]

, 2019
Ensaio clínico PROTEC, Protocolo nº 109MS408Abstract BACKGROUND: Patient-reported outcomes (PRO) and clinical outcomes give a broad assessment of relapsing-remitting multiple sclerosis (RRMS) disease.
Berger, T, Brambilla, L, Brochet, B, Giacomini, PS, Montalbán, X, Salgado, Salgado, AV, e outros   +5 more
core   +1 more source